PLOOSTER MATTHEW R purchased 200.0% of their position (5K shares) of ZEVRA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $24.8K — a major conviction buy. The strongest form of insider conviction signal.
P · 4 purchases
Filed: 5/18/2022ACC: 0001437749-22-012945
Director
Since Apr 2019
+5K
Net shares
Net buyer
$24.8K
Total acquired
4
Open market trades
4B · 0S
4
Total transactions
5K acquired
Non-Derivative Transactions4
Common Stock
Direct
Shares
+695.00
Price / share
$4.94
Trade value
$3.43K
% of position
27.8%
5/18/2022
2.50K→3.19K
Common Stock
Direct
Shares
+915.00
Price / share
$4.95
Trade value
$4.53K
% of position
28.6%
5/18/2022
3.19K→4.11K
Common Stock
Direct
Shares
+3.05K
Price / share
$4.96
Trade value
$15.13K
% of position
74.2%
5/18/2022
4.11K→7.16K
Common Stock
Direct
Shares
+339.00
Price / share
$4.97
Trade value
$1.68K
% of position
4.7%
5/18/2022
7.16K→7.50K
Total
Net shares
+5K
Net value
$24.78K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/18/2022 | P · Purchase | +695.00 | $4.94 | $3.43K | 27.8% | 2.50K | 3.19K |
| Common Stock Direct | 5/18/2022 | P · Purchase | +915.00 | $4.95 | $4.53K | 28.6% | 3.19K | 4.11K |
| Common Stock Direct | 5/18/2022 | P · Purchase | +3.05K | $4.96 | $15.13K | 74.2% | 4.11K | 7.16K |
| Common Stock Direct | 5/18/2022 | P · Purchase | +339.00 | $4.97 | $1.68K | 4.7% | 7.16K | 7.50K |
| Total | +5K | $24.78K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
DirectShares owned1.53K
Common Stock
IndirectShares owned69.00
Total
1.53K direct·69.00 indirect1.60K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 1.53K | Direct |
| Common Stock | 69.00 | Indirect |
| Total | 1.60K | 1.53K direct·69.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported